StemCell Therapy

The 47 rating InvestorsObserver gives to Beam Therapeutics Inc (BEAM) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 41 percent of stocks in the Biotechnology industry, BEAMs 47 overall rating means the stock scores better than 47 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 47 would rank higher than 47 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Beam Therapeutics Inc (BEAM) stock is down -6.18% while the S&P 500 is up 1.19% as of 2:33 PM on Wednesday, Aug 12. BEAM has fallen -$1.46 from the previous closing price of $23.62 on volume of 519,613 shares. Over the past year the S&P 500 is up 0.83% while BEAM is up 18.19%. BEAM lost -$2.68 per share the over the last 12 months.

To screen for more stocks like BEAM click here.

View original post here:
Where Does Beam Therapeutics Inc (BEAM) Stock Fall in the Biotechnology Field? - InvestorsObserver

This entry was posted on August 12, 2020 at 8:48 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |